• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Mucopolysaccharidosis II

Mucopolysaccharidosis II - 30 Studies Found

Completed : The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients
: Hunter Syndrome
: 2014-01-19
Completed : A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723
: Mucopolysaccharidosis II
: 2012-05-17
:
  • Drug: Idursulfase recombinant

Completed : Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
:
  • Hunter Syndrome
  • Mucopolysaccharidosis II<
    : 2008-02-28
    : Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg once-weekly
Completed : Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
: Hunter Syndrome
: 2011-10-06
: Other: No treatment
Completed : Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy
:
  • Hunter Syndrome
  • Mucopolysaccharidosis II<
    : 2008-01-22
    : Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg weekly
Completed : An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
: Hunter Syndrome
: 2009-04-16
: Biological: Idursulfase Patients received idursulfase as prescribed by their physician following locally
Completed : A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
: Hunter Syndrome
: 2009-06-12
:
  • Other: Control 3 dose cohorts

Enrolling by invitation : Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094
: Hunter Syndrome
: 2015-04-01
: Drug: Idursulfase-IT Patients will receive idursulfase-IT treatment once every 28 days at a dose of 10 m
Completed : Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®
: Hunter Syndrome
: 2009-07-09
:
  • Behavioral: Neurobehavioral testing

Active, not recruiting : Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment
: Hunter Syndrome
: 2014-01-17
:
  • Biological: idursulfase-IT 10m

Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.